⚠️ This study is no longer recruiting participants. This information is provided for reference purposes only.
Asthma Exacerbators Study: Researching New Approaches for Severe Asthma
This clinical trial focused on finding new and improved ways to prevent and treat severe asthma exacerbations (flare-ups). The study was a short, 3-month trial looking at airway changes for eosinophilic asthmatic patients requiring biological therapy. All participants received benraluzamab (Fasenra) for 3 months for free, with differences in chest CT scans examined before and after treatment.
Eligibility Criteria
- Diagnosis of severe persistent asthma
- Evidence of eosinophilic asthma
- History of frequent asthma exacerbations requiring emergency room visits or hospitalizations
- Currently using high-dose inhaled corticosteroids and LABA (long-acting beta-agonists) or other controller medications
- Suitable for biological therapy with benraluzamab (Fasenra)
Study Outcomes
This study has concluded enrollment and is in the data analysis phase. For information about current or upcoming clinical trials for severe asthma, please contact our research team.